Barcelona

• Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended recruitment
  2024-517356-35-00 4 2025-07-29 Moderately Active Rheumatoid Arthritis
• Rezafungin for treatment of chronic pulmonary aspergillosis (CPA) in adults with limited treatment options Ended recruitment
  2024-519575-26-00 4 2025-07-25 Chronic pulmonary aspergillosis (CPA)
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended recruitment
  2024-518998-33-00 5 2025-07-23 Ulcerative Colitis
• A Trial of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) Ended recruitment
  2024-519095-66-00 5 2025-07-23 Kidney Transplant Recipients with Late Antibody-Mediated Rejection
• A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended recruitment
  2024-520062-54-00 4 2025-07-23 Chronic Hepatitis D Virus (HDV) Infection
• A Study of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease Ended recruitment
  2024-517143-31-00 4 2025-07-18 Autosomal Dominant Polycystic Kidney Disease
• A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening); … Ended recruitment
  2024-519000-27-00 5 2025-07-17 Hypertension
• A Phase 2 Study of CAL101 in Patients with Idiopathic Pulmonary Fibrosis Ended recruitment
  2024-518339-12-00 4 2025-07-08 Idiopathic Pulmonary Fibrosis
• A Trial to Study the Safety and Efficacy of a New Drug Combination for Weight Loss While Maintaining Muscles Ended recruitment
  2024-519561-22-00 4 2025-07-07 Obesity
• A long-term study to monitor the health status of people with cystic fibrosis who took part in a previous study with BI 3720931 (LenticlairT … Ended recruitment
  2023-504909-37-00 9 2025-07-03 Cystic fibrosis
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m … Ended recruitment
  2024-517020-18-00 4 2025-06-30 Newly diagnosed multiple myeloma according to IMWG criteria
• A Safety, and Tolerability Study of VRDN-003 in Participants with Thyroid Eye Disease (TED) Ended recruitment
  2024-519417-57-00 5 2025-06-25 Thyroid eye disease
• A clinical study of sotatercept in people with pulmonary arterial hypertension Ended recruitment
  2024-518687-12-00 4 2025-06-19 Pulmonary Arterial Hypertension (PAH)
• Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended recruitment
  2024-517817-34-00 9 2025-06-18 Gastric Cancer
• Evaluation of the safety and efficacy of the drug Veonetinib (AL8326) in the post-first treatment of small cell lung cancer, non small cell … Ended recruitment
  2023-509067-24-01 4 2025-06-17 - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Ended recruitment
  2024-517868-33-00 4 2025-06-12 NECTIN4 Amplified Advanced Breast Cancer
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended recruitment
  2024-516051-40-00 4 2025-06-10 Small Cell Lung Cancer (SCLC)
• PLUG-IN. Phase 2 of pembrolizumab combined with enfortumab vedotin for advanced melanoma patients. Ended recruitment
  2024-514163-26-00 4 2025-06-09 Advanced Melanoma
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended recruitment
  2024-517818-15-00 9 2025-06-06 Non-Small Cell Lung Cancer
• A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti­IL­33 mAb) in participants with inadequately-controlled … Ended recruitment
  2024-516815-26-00 5 2025-05-30 Chronic rhinosinusitis with nasal polyps
• A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended recruitment
  2024-518321-15-00 4 2025-05-30 Asthma
• "Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study) … Ended recruitment
  2024-513511-27-00 4 2025-05-29 HR-negative/HER2-negative resectable stage I TNBC.
• A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced … Ended recruitment
  2024-512504-19-00 1 2025-05-28 solid tumors

Showing 1,657–1,680 of 3,391 trials